Jennifer Jarrett - Arcus Biosciences Chief Business and Financial Officer
| RCUS Stock | USD 10.14 0.10 0.98% |
Executive
Ms. Jennifer Jarrett is Director of the Company since January 2019. Ms. Jarrett currently serves as Vice President, Corporationrationrate Development and Capital Markets at Uber, Inc. Ms. Jarrett served as our Chief Operating and Financial Officer from June 2018 to January 2019, and as our Chief Business Officer and Chief Financial Officer from March 2017 to June 2018. From April 2016 to September 2016, Ms. Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc.. Prior to that, Ms. Jarrett spent 20 years in investment banking, most recently as Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for managing their west coast life sciences investment banking practice. Before that, Ms. Jarrett was a Director and Managing Director at Credit Suisse from 2000 to 2010, and an associate at Donaldson, Lufkin Jenrette from 1998 to 2000. During her tenure as an investment banker, Ms. Jarrett covered biotechnology and pharmaceutical companies, primarily in the San Francisco Bay Area. She currently serves on the board of directors of Audentes Therapeutics, Inc., Arena Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc since 2020.
| Age | 50 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 3928 Point Eden Way, Hayward, CA, United States, 94545 |
| Phone | 510 694 6200 |
| Web | https://www.arcusbio.com |
Latest Insider Transactions
Jarrett holds a B.A. in Economics, cum laude, from Dartmouth College and an M.B.A. from Stanford Graduate School of Business. We believe Ms. Jarrett is able to make valuable contributions to our board of directors due to her extensive business experience in the pharmaceutical industry and her service as a director of various other biopharmaceutical companies.Jennifer Jarrett Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jennifer Jarrett against Arcus Biosciences stock is an integral part of due diligence when investing in Arcus Biosciences. Jennifer Jarrett insider activity provides valuable insight into whether Arcus Biosciences is net buyers or sellers over its current business cycle. Note, Arcus Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arcus Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jennifer Jarrett over six months ago Disposition of 34070 shares by Jennifer Jarrett of Arcus Biosciences at 20.11 subject to Rule 16b-3 | ||
Jennifer Jarrett over six months ago Disposition of 34070 shares by Jennifer Jarrett of Arcus Biosciences at 20.11 subject to Rule 16b-3 | ||
Jennifer Jarrett over six months ago Disposition of 1296 shares by Jennifer Jarrett of Arcus Biosciences at 18.62 subject to Rule 16b-3 |
Arcus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4977) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.37 in 2025. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 36.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 211.7 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Jason Amello | Tscan Therapeutics | 56 | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Mark JD | PTC Therapeutics | 64 | |
| Jeanne Gray | Relay Therapeutics | N/A | |
| Carole Huntsman | Madrigal Pharmaceuticals | 60 | |
| Laurent Goux | Krystal Biotech | N/A | |
| Gerhard Bauer | Immix Biopharma | N/A | |
| Zoran JD | Tscan Therapeutics | 55 | |
| Jim Murray | Tscan Therapeutics | N/A | |
| Michael MBA | Annexon | 55 | |
| Yingli Ma | Structure Therapeutics American | 51 | |
| Linda Carter | PTC Therapeutics | N/A | |
| HenkAndre MD | Annexon | N/A | |
| Leiden MBA | Tscan Therapeutics | N/A | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 52 | |
| John Karakkal | Krystal Biotech | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 |
Arcus Biosciences Leadership Team
Elected by the shareholders, the Arcus Biosciences' board of directors comprises two types of representatives: Arcus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcus. The board's role is to monitor Arcus Biosciences' management team and ensure that shareholders' interests are well served. Arcus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer MBA, Chief Officer | ||
| Juan Jaen, President, Co-Founder, Director | ||
| Nicole Lambert, Director | ||
| Patrick Machado, Independent Director | ||
| Jason Barker, Vice President - Finance | ||
| Jennifer Jarrett, Chief Business and Financial Officer | ||
| Eric Matthews, Chief Officer | ||
| Michael Quigley, Director | ||
| Linda Higgins, Director | ||
| Alexander Azoy, VP Officer | ||
| Antoni Ribas, Independent Director | ||
| Holli Kolkey, Vice Communications | ||
| Carolyn JD, General Secretary | ||
| Katherine Bock, Vice Strategy | ||
| Andrew Perlman, Independent Director | ||
| Robert II, Principal CFO | ||
| Eric Hoefer, Chief Commercial Officer & Head of Business Development | ||
| Stephen Young, Senior Biology | ||
| Jonathan Yingling, Chief Officer | ||
| Terry Rosen, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Yvonne Gehring, Senior Operations | ||
| Alexander CPA, VP Officer | ||
| Robert Goeltz, Chief Financial Officer, Principal Financial and Accounting Officer | ||
| Yasunori Kaneko, Lead Independent Director | ||
| David Lacey, Independent Director | ||
| Kathryn Falberg, Independent Director | ||
| Carolyn Tang, General Counsel | ||
| Merdad Parsey, Director | ||
| Christopher Garcia, CoFounder Board | ||
| William Grossman, Chief Medical Officer | ||
| Pia Eaves, Vice Strategy |
Arcus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.03) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 37.3 M | ||||
| Shares Outstanding | 105.15 M | ||||
| Shares Owned By Insiders | 5.59 % | ||||
| Shares Owned By Institutions | 83.80 % | ||||
| Number Of Shares Shorted | 6.38 M | ||||
| Price To Earning | 27.69 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.